BROSSARD, Quebec, June 18, 2019 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (OTCQB:DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce the appointment of Mr. François Côté to its board of directors.
Mr. Côté is currently Vice Chair of the TELUS Fund, an independent organization established to promote health and individual wellness. He is also Lead Director of EXFO Inc., Lead Director of Alithya and Lead Director of Purkinje Inc. He is Executive Chairman of the Board of HZB Pharma Canada. He also serves on the Board of Aspire Food Group and on the Advisor Committee of Groupe Morneau.
Formerly President and CEO at Emergis Inc., a publicly-traded company, Mr. Côté was appointed President, TELUS Health Solutions, following TELUS’ acquisition of Emergis in January 2008. Mr. Côté held the position of President of TELUS Québec before being named Executive Vice President of TELUS and Vice-Chair of TELUS Québec, TELUS Health and TELUS Ventures in 2012 and in 2014-15 as Chair of TELUS Ventures.
“We are delighted to have François joining the Board. Going forward, I am convinced that DIAGNOS will greatly benefit from his vast experience and business relationships in healthcare and finance,” said Mr. Georges Hebert, Chairman of the board of directors of DIAGNOS.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time. CARA complies with local regulations, is FDA cleared for commercialization in the United States of America is Health Canada licensed for commercialization in Canada and is CE marking compliant in Europe.
Additional information is available at www.diagnos.com and www.sedar.com
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
